<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="829">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04339426</url>
  </required_header>
  <id_info>
    <org_study_id>HRI-COVID-19-Anti-Malarial-001</org_study_id>
    <nct_id>NCT04339426</nct_id>
  </id_info>
  <brief_title>Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection</brief_title>
  <official_title>Open-Label, Non-Randomized Study to Evaluate Anti-Malarial/Anti-Infective Combination Therapies in Patients With Confirmed COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HonorHealth Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HonorHealth Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate anti-malarial/anti-infective single-agent and in combination for
      patients with confirmed COVID-19 infection. The first combination to be evaluated is
      atovaquone and azithromycin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, non-randomized study to evaluate anti-malarial/anti-infective
      single-agents and combination therapies for patients with confirmed COVID-19 infection
      requiring therapy as determined by risk factors for complication (age, comorbid illness) or
      the presence of respiratory compromise. The first combination to be evaluated is
      atovaquone/azithromycin. Other combinations may be added to the study at future amendments as
      information of potential benefit arises. The first part of the study will enroll 25 evaluable
      male and female patients 18 years of age or older with confirmed COVID-19 infection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Virology Cure Rate</measure>
    <time_frame>10 days</time_frame>
    <description>COVID-19 serology testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of GI adverse events</measure>
    <time_frame>47 days</time_frame>
    <description>Measure incidence of diarrhea, vomiting, nausea and constipation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Toxicity</measure>
    <time_frame>10 days</time_frame>
    <description>12-Lead ECG daily if QTc &gt;500 msec</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in WBC w Diff, B cells, T cells, NK cells</measure>
    <time_frame>10 days</time_frame>
    <description>Measure blood counts</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in cytokine levels, IL-1, IL-6, IL-12, IL-18, TNF-a</measure>
    <time_frame>10 days</time_frame>
    <description>Measure changes in plasma cytokines throughout course of infection</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Atovaquone/Azithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atovaquone 750 mg PO Q12H for up to 10 days Azithromycin 500 mg PO Day 1 followed by 250 mg PO daily for up to 10 days (Days 2-10)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atovaquone/Azithromycin</intervention_name>
    <description>Atovaquone 750 mg PO Q12H for up to 10 Days Azithromycin 500 mg PO Daily 1 followed by 250 mg PO Daily for up to 10 days (days 2-10)</description>
    <arm_group_label>Atovaquone/Azithromycin</arm_group_label>
    <other_name>Mepron/Zithromax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and Female patients age 18 years or older

          -  COVID-19 confirmed positive test results

          -  High risk for complications including with Medium (5-6) or High (More than or equal to
             7) NEWS score

          -  Hematology criteria: ANC &gt;500 cells/mcl, HGB &gt;9 g/dl, Platelet count &gt;75,000/mcl

          -  Metabolic criteria: Serum creatinine &lt;2.0 mg/dl or calculated creatinine clearance
             (using Cockcroft-Gault) &gt;30 ml/min, AST/ALT &lt;5x ULN AND Total Bilirubin WNL (for
             patients with Gilbert's disease, direct bilirubin &lt;ULN)

        Exclusion Criteria:

          -  COVID-19 negative test result

          -  Inability to adhere to study protocol requirements

          -  Inability to provide informed consent

          -  Other acute or chronic medical or psychiatric condition that in the judgment of the
             investigator would make the participant inappropriate to take part in the study

          -  Pregnant and breastfeeding individuals

          -  QTc interval greater than 470 msecs at baseline

          -  History of hypersensitivity to atovaquone and/or azithromycin.

          -  History of known intolerance to atovaquone and/or azithromycin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Gordon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HonorHealth Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Lewandowski, RN</last_name>
    <phone>480-583-0760</phone>
    <email>klewandowski@honorhealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heather Lane</last_name>
    <phone>480-323-1081</phone>
    <email>hlane@honorhealth.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HonorHealth</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Lewandowski, RN</last_name>
      <phone>480-583-0760</phone>
      <email>klewandowski@honorhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Heather Lane</last_name>
      <phone>480-323-1081</phone>
      <email>hlane@honorhealth.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 7, 2020</study_first_submitted>
  <study_first_submitted_qc>April 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2020</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Atovaquone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

